TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral ther

Prevail Partners, LLC to invest again in Hemogenyx PharmaceuticalsPrevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical studyLONDON, UNITED KINGDOM / ACCESSWIRE / October 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces tha tPrevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest a total of $350,000 (approximately £269,000) in the Company through a subscription for ordinary shares in the Company at a price of US$0.075 per share (approximately 5.6p). This follows a similar investment in the Company by Prevail Partners announced on 18 September 2024. The subscription price represents a premium of approximately 275% to the Company's closing share price on 1 October 2024.The subscription will take effect in March 2025 ahead of the planned HEMO-CAR-T pediatric study. This will follow the initiation of the adult clinical trial in HEMO-CAR-T at the MD Anderson Cancer Center, Texas, which is expected to commence later this year. The agreement governing the subscription contains customary warranties from the Company and Prevail Partners.The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed an amendment to the Master Service and Technology Agreement ("MSTA"), (the "Amendment") with Prevail InfoWorks, Inc

A pharmaceutical startup aiming to treat Androgenetic Alopecia, a type of genetic hair loss, has raised a $4 million funding round that included the New Brunswick Innovation Foundation.Founded in 2013 by Dr. Houfar Sekhavat and pharmacist Peter Ford, Dieppe, N.B.-based Triple Hair also received approval from European regulators to start the final stage of trials for its flagship prescription spray, Therapy-07, earlier this month. In a statement, Triple Hair said the money will go towards funding that research, with Health Canada approval for the trials having been granted last summer.Alongside NBIF, the other main investors in the round were Prevail Partners, a life sciences fund out of Philadelphia, and the Quebec government through its Impulse PME equity funding program. In its own statement, NBIF said its share of the raise amounted to $200,000.“This is an important milestone for Triple Hair, both in terms of securing funding and the recognition of the potential value of Therapy-07 by reputable financial institutions,” said CEO Jean-Philippe Gravel. “These funds will notably enable us to prepare the Phase III clinical trials planned for Therapy-07.”Androgenic Alopecia can affect both men and women, but is marked by a gradual thinning of the hair that begins in the centre of the head, unlike typical male-pattern baldness, which starts at the forehead and temples. The condition is genetic and caused by the body having an excessive response to androgens — sex hormones.Previous testing by Triple Hair has suggested Therapy-07 could produce significant hair regrowth in about four-fifths of patients, while established market leaders like Rogaine typically aim to halt hair loss, but do not reliably regrow it